Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma
To the Editor:
Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) comprising an anti-CD30 chimeric IgG1 antibody conjugated to the antimicrotubule agent, monomethyl-auristatin-E (MMAE), by a proteasecleavable-linker. 1 Binding of BV to CD30 on the cell surface initiates internalization of the ADC-CD30 complex, which then releases MMAE via proteolytic cleavage into the lysosome. Binding of MMAE to tubulin disrupts the microtubule network and induces cell cycle arrest and apoptotic death of CD30 + tumor cells. 2 BV is approved for the treatment of some CD30 + hematological malignancies. 3, 4 Hypersensitivity reactions (HSRs) to several clinical monoclonal antibodies (MoAbs) have been reported. 5 Few were related to BV, but its approval is recent. 4, 6 Reactions of this kind are of concern when no therapeutic alternatives are available. 7, 8 To overcome HSR to MoAbs, successful rapid desensitizations (RDs) have been reported. 9 An RD allows the gradual increasing of the rate and concentration of drugs over several hours. Here, we describe a successful RD to BV in a 34-year-old man with scleronodular stage IV-B Hodgkin lymphoma (HL), refractory to several lines of chemotherapy including BEACOPP and ICE.
He responded partially to a gemcitabine/vinorelbine/ liposomal-adriblastine regimen and received a tandemdouble autologous stem cell transplantation (ASCT) that was conditioned, respectively, by BEAM and BAM (busulfan-cytarabine-melphalan). Despite this, the patient progressed rapidly after the last ASCT. Based on good results observed in refractory HL, BV was initiated at the dose of 1.8 mg/kg every three weeks. 7 The first infusion was well tolerated, but 10 min after starting the second the patient experienced a severe HSR with dyspnea, throat tightness, hypotension (80/60 mmHg), tachycardia (133 bpm), SaO2 95% at room air (Table 1) . He responded well to dexchlorpheniramine, hydrocortisone, and methylprednisolone. No epinephrine was required. Because there was no therapeutic alternative, we planned to pursue BV administration using a 16-step-RD.
9,10 Our patient gave his informed and written consent.
The 16-step-RD protocol took place under the supervision of an allergist and a hematologist with one-on-one nurse support. Before BV administration, we performed skin tests to better characterize the kind of HSR observed. They were made three weeks after the second administration of BV in order to minimize the likelihood of false-negative results. For the prick test, a drop of BV solution (5 mg/mL) was applied to the volar surface of the forearm. For intradermal reactions, we used growing concentrations of BV, 0.03 mL of a 1/100, 1/10 and a full-strengh solution of 5 mg/mL. Histamine (10 mg/mL) and 0.9% NaCl were used as positive and negative controls, respectively. A good intravenous access, vital signs, and pick -flow were checked. At bedside, a desensitization kit with epinephrine was available. Pre-medication included cetirizine 10 mg, aspirin 500 mg, montelukast 10 mg, and ranitidine 150 mg. BV solutions: four bags of 250 mL (solutions 1-4) in 0.9% NaCl were administered intravenous in 16 consecutive steps (Table 2) . At each step, the BV flow rate was increased 2 to 2.5 fold. Steps 1-15 took 15 min each, and step 16 took longer until the targeted dose was reached (Table 2) .
Skin tests were considered as positive for intradermal reactions at all the BV concentrations used. Based on recommendations, the patient pursued BV by a RD. 9 The first attempt (RD1) was aborted shortly after starting step 15 when the patient again experienced a severe HSR (Table 1, Figure 1 (a)). We then decided to make a new attempt (RD2) with a lower dose (1 mg/kg) that was successfully infused despite a mild reaction that responded well to corticosteroids and antihistamines (Figure 1(b) ). For subsequent administrations, we slowed-down the infusion rate of Solution 4 by adding a new step, implying a 17-step-RD ( Table 2 ). The following cycles at 1.5 mg/kg (RD3) and 1.8 mg/kg (RD4 and later on) were given on this basis. For the management of HSR during RDs, from RD3 (before Solution 4), we introduced a prophylactic treatment with methylprednisolone 120 mg and dexchlorpheniramine (5 mg). No reaction was observed from RD3 (Table 1, Figure 1(c) ). As tolerance was good we decided from RD6 to increase the BV rate infusion of Solutions 1 to 3 (steps 1-12) (Figure 1(d) and (e)). This also implied the calculation of a proportionally shorter duration for each step in order to keep a similar BV dose infused to the patient at each step. In total, 16 BV cycles were administered. This successful administration was associated with a favorable antitumor response for 10 months before conducting an HLA-mismatch allo-transplantation.
Infusion adverse effects of BV were reported in 14% of the patients in phase I and phase II studies. 4, 8 A reaction defined as anaphylactic was observed in two patients in a phase I study. 7 In one of them the reaction occurred during the second administration of BV as in the case of our patient. We consider that he presented a type-1 mast-cell/Immunoglobulin E (IgE)-mediated Table 2 . Brentuximab vedotin solutions: four bags of 250 mL (solutions 1-4) were administered IV in 16 consecutive steps. The amount (in mg) of BV that was present in each dilution bag increased from solution 1 to 4. The BV flow-rate was increased 2 to 2.5 fold. Steps 1-15 took 15 min each and steps 16 and 17 took longer until the targeted dose was reached.
Step Solution (bags) HSR based on the positive cutaneous tests and the occurrence of HSR at the second infusion implying a necessary sensitization. Rapid clearance of BV because of the high tumor mass could have facilitated its development. Total IgE levels and the blood eosinophil count were high but these cannot be considered as specific markers. Moreover, tryptase and histamine levels were normal during RD1-2. Recently, BV administration after prophylaxis was pursued in two reported cases of severe infusion HSR. In our opinion, this involved a high degree of risk. 6 In another recently reported case, an RD protocol was set up to overcome a severe HSR to BV in a patient with anaplastic large cell lymphoma ALK neg . 11 This patient experienced the HSR to BV after being rechallenged to BV 28 months after the first infusion. However, it was only after the third infusion (30 months after the first infusion) that a severe HSR was observed, similar to the case we are reporting. The authors reported subsequent severe HSR after the fourth and fifth cycles of BV. In all these cycles, the BV infusion had to be stopped. Only from the seventh infusion of BV the RD protocol that was set up allowing a full delivery of BV.
11
Regarding our own experience, we decided to set up an RD protocol earlier in the clinical history of sensitization to BV and we decided also not to deliver full doses of BV during the first RD cycles. Moroever, we tried to collect more laboratory evidence in order to better understand the immunological aspects involved in the HSR observed in our patient. The 17-step-RD protocol we elaborated was adapted from those reported by Castells et al. and we think this is an important consideration because the clinical situation of patients with HSR to MoAbs is not always similar and medical teams should be able to integrate this into their clinical practice. Based on our knowledge, the case we are reporting appears to be the first succesful RD protocol to BV in a patient with Hodgkin disease. Although we cannot specify to which component of the ADC molecule our patient became sensitized, from the clinical point of view this strategy had a significant impact on the survival of this high-risk patient. Thus, this RD experience we are reporting might represent a safer solution for patients presenting an HSR who need to be treated with BV.
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